BibTex format
@article{Russell:2021:10.1016/S2666-5247(21)00090-2,
author = {Russell, CD and Fairfield, CJ and Drake, TM and Turtle, L and Seaton, RA and Wootton, DG and Sigfrid, L and Harrison, EM and Docherty, AB and de, Silva T and Egan, C and Pius, R and Hardwick, HE and Merson, L and Girvan, M and Dunning, J and Nguyen-Van-Tam, JS and Openshaw, PJM and Baillie, JK and Semple, MG and Ho, A},
doi = {10.1016/S2666-5247(21)00090-2},
journal = {The Lancet Microbe},
pages = {E354--E365},
title = {Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study},
url = {http://dx.doi.org/10.1016/S2666-5247(21)00090-2},
volume = {2},
year = {2021}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BackgroundMicrobiological characterisation of co-infections and secondary infections in patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe microbiologically confirmed co-infections and secondary infections, and antimicrobial use, in patients admitted to hospital with COVID-19.MethodsThe International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study is an ongoing, prospective cohort study recruiting inpatients from 260 hospitals in England, Scotland, and Wales, conducted by the ISARIC Coronavirus Clinical Characterisation Consortium. Patients with a confirmed or clinician-defined high likelihood of SARS-CoV-2 infection were eligible for inclusion in the ISARIC WHO CCP-UK study. For this specific study, we excluded patients with a recorded negative SARS-CoV-2 test result and those without a recorded outcome at 28 days after admission. Demographic, clinical, laboratory, therapeutic, and outcome data were collected using a prespecified case report form. Organisms considered clinically insignificant were excluded.FindingsWe analysed data from 48 902 patients admitted to hospital between Feb 6 and June 8, 2020. The median patient age was 74 years (IQR 59–84) and 20 786 (42·6%) of 48 765 patients were female. Microbiological investigations were recorded for 8649 (17·7%) of 48 902 patients, with clinically significant COVID-19-related respiratory or bloodstream culture results recorded for 1107 patients. 762 (70·6%) of 1080 infections were secondary, occurring more than 2 days after hospital admission. Staphylococcus aureus and Haemophilus influenzae were the most common pathogens causing respiratory co-infections (diagnosed ≤2 days after admission), with Enterobacteriaceae and S aureus most common in secondary respiratory infections. Bloodstream infections were most frequently caused by Escherichia coli a
AU - Russell,CD
AU - Fairfield,CJ
AU - Drake,TM
AU - Turtle,L
AU - Seaton,RA
AU - Wootton,DG
AU - Sigfrid,L
AU - Harrison,EM
AU - Docherty,AB
AU - de,Silva T
AU - Egan,C
AU - Pius,R
AU - Hardwick,HE
AU - Merson,L
AU - Girvan,M
AU - Dunning,J
AU - Nguyen-Van-Tam,JS
AU - Openshaw,PJM
AU - Baillie,JK
AU - Semple,MG
AU - Ho,A
DO - 10.1016/S2666-5247(21)00090-2
EP - 365
PY - 2021///
SN - 2666-5247
SP - 354
TI - Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
T2 - The Lancet Microbe
UR - http://dx.doi.org/10.1016/S2666-5247(21)00090-2
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000682975600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://www.sciencedirect.com/science/article/pii/S2666524721000902?via%3Dihub
VL - 2
ER -
